Skip to main content
Signal8

Cardiol Therapeutics Inc. (CRDL)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Drug Manufacturers - Specialty & Generic

Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc.

NASDAQ:CRDLHealthcare
-6.34%$0.8899
Mkt Cap$113.63M
EV-
Float112.16M
O/S127.69M
VOL439K sh
$ Vol$395K
RVOL0.84×
Inst Own31.9%
Net Cash/Sh-
Dilution
Cardiol Therapeutics Inc. logoNASDAQ:CRDL$0.8899-6.34%
Historical Data
DateOpenHighLowCloseVolume
Nov 19, 20260.95280.95280.87010.8899439,337
Nov 18, 20260.98780.99400.93250.9501309,736
Nov 17, 20260.97000.99160.95000.9718347,442
Nov 16, 20261.011.040.95350.9798278,550
Nov 13, 20261.021.040.97021.00451,724
Nov 12, 20261.011.070.97011.04441,953
Nov 11, 20261.051.071.001.01514,215
Nov 10, 20261.011.051.011.02311,246
Nov 9, 20260.99001.060.97521.03406,707
Nov 6, 20260.97481.000.94000.9950596,746
Nov 5, 20261.001.030.91500.9265733,919
Nov 4, 20261.051.060.99511.01870,985
Nov 3, 20261.051.071.031.05370,813
Nov 2, 20261.111.121.031.04740,367
Oct 30, 20261.171.171.101.11711,704
Oct 29, 20261.171.221.161.17557,093
Oct 28, 20261.161.181.131.17450,622
Oct 27, 20261.121.161.121.14313,852
Oct 26, 20261.121.151.111.12580,157
Oct 23, 20261.151.161.101.121,101,793
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
2
HOLD
0
SELL
0
TOTAL2
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
31.9%
Institutional
(61)
0.0%
Insiderⓘ
(0)
0.0%
5%+ Owners
(0)
68.1%
Unattributed (incl. retail)ⓘ
Institutional31.9%
Unattributed (incl. retail)68.1%
Sources: 13F, 13D/13GO/S: 127.7M · as of 12 Nov 2026 · SEC filings
Insiders & Institutional Holders
About

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD).

Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.

Key Metrics
Market Cap$113.63M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership31.87%

based on 127.69M shares outstanding

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
CountryCACA
IPO DateJan 15, 2019
Shares Outstanding127.69M
Authorized Shares
Float112.16M
Float (other source)115.36MMarket-data free float · as of 2026-10-02
Float (bounds only)at most 124.98M
52-Week Range
$0.8701$2.34
$0.8899(1st percentile)
Volume
Average Daily Volume525.33K
439.34K today vs 525.33K avg(-16%)

30d Avg

525.33K

60d Avg

1.04M

90d Avg

1.20M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of CRDL as of Dec 31, 2025 records an effective F-10 shelf registration (effective Sep 16, 2026), an at-the-market sales agreement dated Nov 3, 2026, 1 outstanding warrant series and a PIPE closed Jan 23, 2026, from SEC filings. Cardiol Therapeutics Inc. (NASDAQ: CRDL) traded at $0.8899 on Nov 19, 2026, down 6.34% from the previous close of $0.9501. 52-week range: $0.8701 to $2.34. The company is in the Healthcare sector (Drug Manufacturers - Specialty & Generic).